Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 1-20 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 1 | ICEYE highstrong | Opp 9 Risk 3 | Thesis: Recent very large funding, high stated valuation, and evidence of expanding sovereign SAR demand support a durable multi-quarter scaling thesis. Why now: On June 9, 2026 ICEYE disclosed a €450 million primary Series F at valuation above €10 billion, with total round size above €1 billion including secondary, and later June context also referenced a €300 million revolving credit facility and additional sovereign satellite demand; those are recent business-state signals for a 1 year+ horizon. Evidence
Caveats: Some support is supporting article context rather than company-specific positive evidence. Several supporting demand/customer references are undated, so recency is uncertain for those claims. |
| 2 | SpaceX highstrong | Opp 9 Risk 4 | Thesis: SpaceX has the strongest evidence-set-backed long-horizon opportunity because it secured multiple large, recent government awards that deepen its role as a core military and civil space infrastructure provider, with contract scope spanning surveillance, communications backbone, and additional NASA crew missions. Why now: The timing is supported by late-May 2026 contract awards: a $2.29 billion Space Force data-network award dated May 26, 2026 and a $4.16 billion Space Force SB-AMTI award dated May 29, 2026/May 30, 2026, plus NASA's plan dated May 24, 2026 to add missions to SpaceX's commercial crew contract, all of which indicate durable backlog expansion and franchise entrenchment over a 1 year+ horizon. Evidence
Caveats: The reviewed sources' available source fields contain no direct positive or negative events for SpaceX; opportunity is inferred from high-materiality neutral facts and article summaries. Ticker mapping is noisy in the reviewed sources: SpaceX is shown with ticker TSLA, which should not be treated as validated public-company identity here. |
| 3 | Apex Space mediummedium | Opp 8 Risk 4 | Thesis: Apex has the strongest opportunity case in this screen because multiple dated June 2026 sources say it raised over $200 million at a $2.3 billion valuation specifically to scale high-rate satellite bus production for proliferated constellations, and a separate dated June 2026 article says Northrop partnered with Apex on space-based interceptors for Golden Dome. Together, these indicate fresh capital, scaling intent, and positioning with government/defense demand vectors over a 1 year+ horizon. Why now: Why now is strong because the key financing evidence is dated June 5, 2026 and the Northrop partnership article is dated June 1, 2026, making both recent within the 90-day recent evidence window and relevant to a 1 year+ scaling thesis. The June 5 financing event is later than the April 16 capacity/context article and therefore better reflects current business state. Evidence
Caveats: Most available evidence is neutral fact or supporting article context, not explicit positive events. Same-day repeated articles around the fundraise are not independent proof beyond corroboration. Some context sources are company-issued or article-level summaries, which are weaker than direct events. |
| 4 | AST SpaceMobile, Inc. highstrong | Opp 8 Risk 5 | Thesis: AST SpaceMobile has strong long-horizon opportunity because it achieved a critical regulatory milestone for a 248-satellite direct-to-device constellation and continues to show ecosystem buildout through operator partnerships and stated constellation scale targets. Why now: The key timing event is the FCC authorization dated April 21, 2026/April 22, 2026 granting authority for up to 248 satellites and direct-to-device service, a milestone that can unlock U.S. commercial and government use cases over a 1 year+ horizon. Later-dated company-site context on June 23, 2026 also says AST has nearly 60 operator partners and targets direct broadband to standard smartphones. Evidence
Caveats: Much of the evidence is company, press-release, or article-context based rather than independent hard performance metrics. The reviewed sources cites a target of 45 to 60 BlueBird satellites by end-2026 in article summary context, but this is not available as a direct structured fact here. |
| 5 | BlackSky Technology Inc. highstrong | Opp 8 Risk 4 | Thesis: BlackSky has the strongest recent opportunity evidence in the screen: a multi-year sole-source $99 million U.S. government IDIQ tied to next-generation Earth observation and space domain awareness development, plus a separate $25 million multi-year assured contract with a major international defense customer. Together these indicate current government demand, product validation, and longer-horizon backlog/ARR support. Why now: The why-now is supported by two dated recent wins inside the recent evidence window: on March 31, 2026 BlackSky said it received a multi-year sole-source $99 million U.S. government IDIQ and initial $2 million funding for advanced large-aperture payload design; on April 22, 2026 it announced a competitive $25 million multi-year assured contract with a major international defense customer and said it had four Gen-3 satellites on orbit and was rapidly deploying Gen-3 capacity while driving up backlog and annual recurring revenue. Evidence
Caveats: The $99 million figure is an IDIQ ceiling, not fully funded revenue at announcement; only an initial $2 million was specifically disclosed. Some corroboration repeats the same underlying announcement and should not be treated as independent evidence |
| 6 | Boeing highstrong | Opp 8 Risk 2 | Thesis: Boeing has the strongest opportunity evidence in this screen because the reviewed sources includes recent company-linked fact evidence that it won a $2 billion U.S. Space Force contract to build two next-generation MUOS communications satellites. The award covers design, development, production, testing, and on-orbit support for a critical military SATCOM network, with launches no earlier than 2031 and 2032 and constellation support through 2035. That is a material, durable space/defense win aligned with the 1 year+ horizon Why now: Why now is strong because the contract was reported on June 23-25, 2026, making it recent within the 90-day recent evidence window, and it represents a fresh, material U.S. defense-space award with multiyear strategic relevance Evidence
Caveats: Some corroborating rows are supporting article context and should not be overcounted as independent confirmation. Program financial benefits may phase in over a long cycle given first delivery timing in 2031. |
| 7 | Capella Space highstrong | Opp 8 Risk 4 | Thesis: Capella Space has the strongest opportunity profile in this screen because the reviewed sources includes a dated, company-specific contract fact showing it won a roughly $49 million SDA contract to build two satellites for a military communications demonstration, adding to evidence that it operates advanced SAR satellite capabilities and serves government and strategic customers. Why now: The April 8, 2026 SDA award is recent within the recent evidence window and is directly relevant to a 1 year+ horizon because it funds spacecraft design and development for a government demonstration program. Later context articles in April-June 2026 continue to depict Capella as an operating SAR platform with defense exposure. Evidence
Caveats: The positive contract evidence is classified as a neutral supporting fact in the reviewed sources, so direction is inferred from the business substance rather than explicit positive polarity labeling. Several contextual articles mention a planned acquisition or subsidiary status, but time-sensitive ownership/public-status interpretations should be treated cautiously because not all such references are direct, dated transaction-closing evidence. For example, and |
| 8 | Impulse Space mediummedium | Opp 8 Risk 4 | Thesis: Impulse Space has the strongest opportunity setup in this screen based on recent, company-linked financing evidence that it raised $500 million in Series D funding to scale production of orbital transfer vehicles, with article context also indicating expansion to support growing commercial and government demand. For a 1 year+ horizon, that capital base can support production scale-up and program execution. Why now: The catalyst is recent and dated: on June 2, 2026/June 3, 2026, Impulse Space disclosed a $500 million Series D and total capital raised above $1 billion, which is highly relevant for a 1 year+ scaling thesis. Evidence
Caveats: Some supportive items are supporting article context and should not be treated as independent confirmation if repeating the same financing announcement. Older commercial contract and government contract references in representative articles are outside the 90-day recent evidence window and therefore not primary recency support here. |
| 9 | Katalyst Space Technologies highstrong | Opp 8 Risk 6 | Thesis: Katalyst Space Technologies has a strong opportunity profile because the reviewed sources show recent evidence of both mission relevance and financing: a NASA Phase III SBIR contract to develop a rescue concept for the Neil Gehrels Swift Observatory and a later June 23, 2026 report that it raised $12 million to develop its NEXUS robotic spacecraft and expand satellite servicing. Why now: Why now is strong because the latest dated evidence on June 23, 2026 adds new capital after the May 29, 2026 NASA-related mission context, supporting a 1 year+ thesis that the company is moving from concept credibility toward funded development in on-orbit servicing. Evidence
Caveats: Part of the positive case comes from company-issued materials and supporting article context rather than independent positive evidence. The May 29, 2026 article includes a dated source date but describes an announcement text beginning 'August 11, 2025'; chronology should therefore be read carefully, with the treated as the recency marker for this retrieved item. Citation |
| 10 | Northrop Grumman Corp mediumstrong | Opp 8 Risk 3 | Thesis: Northrop Grumman has the strongest reviewed sources-supported opportunity profile in this screen due to multiple recent space-defense catalysts: inclusion in the April 8, 2026 Andromeda RG-XX awards, a June 1, 2026 partnership with Apex on Golden Dome space-based interceptors, and a June 22, 2026 $398M Space Force contract for the Enhanced Protected Tactical SATCOM Prototype. Together these support a durable 1 year+ defense-space demand thesis. Why now: The setup is current and cumulative: April 8, 2026 Andromeda participation, June 1, 2026 Golden Dome interceptor partnership, and June 22, 2026 award of a $398M protected satcom contract all fall within the 90-day recent evidence window and point to sustained momentum. Evidence
Caveats: The reviewed sources does not provide direct business impact breakdowns beyond the $398M contract article. Some support is supporting article context rather than dated events. |
| 11 | Observable Space mediummedium | Opp 8 Risk 4 | Thesis: Observable Space has the strongest positive setup in this screen because the reviewed sources contain dated evidence that it raised a $90 million Series A and secured a $94 million U.S. Space Force optical-systems contract, supporting capital availability, customer validation, and potential multi-quarter execution runway. Why now: The timing is favorable because on May 28, 2026 the company was reported to have both closed a $90 million Series A and announced a $94 million U.S. Space Force award, with additional follow-on reporting on June 9, 2026 indicating the contract landed just weeks after the raise, suggesting a recent step-change in funding and government traction for a 1 year+ horizon Evidence
Caveats: Positive direction is inferred from neutral facts plus article summaries; the reviewed sources does not provide explicit positive events. Same-article repeated rows are not independent confirmation. Supporting web-search evidence is context and should be treated below directly cited company evidence. |
| 12 | PLD Space highstrong | Opp 8 Risk 4 | Thesis: PLD Space has recent financing, strategic customer/investor validation, infrastructure investment, and a first commercial launch contract, all of which support a durable launch-scaling thesis over the next year-plus. Why now: The reviewed sources show a sequence of material developments: €180 million Series C on March 4, 2026, €30 million EIB venture debt signed April 7, 2026 and reported May 6, 2026/04-07, first commercial contract reported May 21, 2026, and €35 million Kourou launch-complex investment on June 1, 2026 while MIURA 5 remained on track for a late-2026 first test flight. That is strong state-change evidence for a 1 year+ horizon. Evidence
Caveats: Risk evidence is partly inferred from dependency on future launch milestones rather than a disclosed adverse event. Most support is supporting article context, though the chronology is consistent and material. |
| 13 | Quantum Space mediummedium | Opp 8 Risk 5 | Thesis: Quantum Space has the clearest evidence-backed opportunity profile in this screen: within the recent evidence window it announced a SPAC merger expected to bring substantial capital and public-market access, and later won a Pentagon-funded orbital refueling spacecraft contract built on its Ranger platform. Those developments support a durable 1 year+ thesis around funding access, national-security positioning, and product relevance in on-orbit logistics. Why now: The evidence is recent and sequenced: on June 8, 2026 Quantum Space announced its planned SPAC merger and expected Nasdaq listing under QSPC Evidence
Caveats: Most available evidence is external overlay context rather than first-party positive or negative events. Same-theme repetition across June articles is not independent confirmation. Ticker QSPC is prospective after the expected SPAC close per June 8, 2026 evidence, not confirmed as already trading under that symbol |
| 14 | True Anomaly highstrong | Opp 8 Risk 4 | Thesis: True Anomaly has the strongest opportunity profile in this screen because the reviewed sources contain dated, company-linked evidence that it raised $650 million in Series D financing at a $2.2 billion valuation on April 28, 2026 and was selected by the U.S. Space Force for the Space-Based Interceptor program on May 4, 2026. For a 1 year+ horizon, that combination of fresh capital plus program participation supports scaling, product development, and defense-space positioning. Why now: The recent sequence matters: on April 28, 2026, True Anomaly announced a $650 million Series D at a $2.2 billion valuation, also. Then on May 4, 2026, a dated article said the company was selected by the U.S. Space Force Space Systems Command for the Space-Based Interceptor program. That capital-plus-program sequence is directly relevant to a long-horizon growth thesis. Evidence
Caveats: Most evidence is external overlay context/facts rather than primary data source direct events. Several sources repeat the same April 28 financing story and are not independent confirmation of different events. The company-site article is undated, so recency-sensitive claims from it should be treated cautiously. |
| 15 | Anduril Industries mediummedium | Opp 7 Risk 5 | Thesis: Anduril has a credible 1 year+ opportunity setup from recent participation in major U.S. defense-space programs and fresh financing context. Recent article context says Anduril was among companies awarded Space Force Andromeda contracts for the RG-XX satellite effort on April 8, 2026, and a later article says Anduril raised a $5B Series H round published June 19, 2026, supporting capital availability for scaling in defense-space programs. Why now: The timing is supported by recent 2026 article context around Space Force Andromeda participation and the June 19, 2026 financing context, which together suggest active momentum over the last quarter. Evidence
Caveats: Most evidence is weak context-only article evidence, not direct positive events in the available ranking rows. |
| 16 | Astroscale mediummedium | Opp 7 Risk 4 | Thesis: Astroscale has the clearest 1 year+ opportunity setup in this screen: within the recent evidence window article context shows recent funding support, strategic growth financing for medium-to-long-term expansion, and a shift from demos toward repeatable commercial missions, including defense-related servicing and a 2027 inspection mission pipeline. Why now: Recency is the main reason: on June 22, 2026 SpaceNews said Astroscale was 'working to transition from technology demonstrations to a regular series of missions, bolstered by a recent capital infusion' and saw 'repeatable business opportunities' particularly among defense customers. On May 19, 2026 financing materials said the company would raise 30.6 billion yen to secure medium-to-long-term growth funding 'in anticipation of transitioning to a phase of continuous order acquisition'. On April 6, 2026 Astroscale revealed its ISSA-J1 mission scheduled for launch in 2027. Evidence
Caveats: Most within the recent evidence window evidence is supporting article context, not structured company-specific events; reviewed sources warns supporting article context is weaker than direct event/fact evidence. Same-article repeated weak-context rows are not independent confirmation. Older 2023 and 2025 articles exist in representative articles but fall outside the 90-day recent evidence window for ranking use. |
| 17 | ClearSpace mediummedium | Opp 7 Risk 3 | Thesis: Best opportunity profile in this screen based on multiple dated article-context items showing the company remains active in in-orbit servicing/debris removal, has financing support, is ramping toward ClearSpace-1, and is expanding into defense-adjacent partnership activity. For a 1 year+ horizon, that combination supports a credible strategic growth and market-positioning thesis. Why now: Why now is supported by recent dated context: on June 24, 2026, SpaceNews reported ClearSpace signed an MOU with Shield Space to develop sovereign space defense capabilities for the UK and allies, indicating adjacent market expansion. On May 19, 2026, the company site said it had finalized a EUR 26.7 million Series A and was ramping operations ahead of ClearSpace-1 scheduled to launch in 2026. These dated items fit a 1 year+ horizon because they point to ongoing commercialization and mission preparation. Evidence
Caveats: Most evidence is supporting article context, not direct positive events. The financing article published on May 19, 2026 references January 19, 2023 for the Series A round, so funding recency versus page recency should not be conflated. |
| 18 | Cowboy Space mediummedium | Opp 7 Risk 4 | Thesis: Cowboy Space has the strongest positive evidence in this screen: a large Series B financing at a substantial valuation, explicit plans to build vertically integrated rockets plus orbital data-center infrastructure, and stated hiring/buildout activity. That combination supports a durable 1 year+ strategic opportunity thesis. Why now: Multiple dated articles on May 11, 2026 report Cowboy Space raised $275 million in Series B financing at a $2 billion valuation to build rockets with orbital data-center upper stages, and a TechCrunch article says the company is standing up its own rocket program with a first launch expected before end-2028 Evidence
Caveats: The reviewed sources contain no explicit negative event evidence; risk is inferred from execution complexity and long timeline, not from adverse events. Several supporting rows repeat the same May 11, 2026 financing story and are not independent confirmation. Some supporting article context is undated and should be treated cautiously for recency. |
| 19 | Dawn Aerospace mediummedium | Opp 7 Risk 3 | Thesis: Dawn Aerospace has the strongest opportunity evidence in this screen because a recent dated company article says it closed a $25 million Series B at a $195 million post-money valuation to accelerate global expansion of reusable space transportation. The funding is directly tied to rollout, commercial scaling in the US and Europe, and support for an expanding international customer base, which fits a 1 year+ horizon. Why now: The key catalyst is recent and explicit: on June 16, 2026 the company announced the Series B close and said the proceeds will finance global rollout and scaling of commercial and operational teams in the US and Europe. Evidence
Caveats: Evidence comes from a company-published article, so it is not fully independent. No direct structured positive event row is provided beyond supporting article context. |
| 20 | Eutelsat Communications SA mediummedium | Opp 7 Risk 4 | Thesis: Eutelsat has a strong long-horizon opportunity case from the reviewed sources' membership rationale stating it is supervising a 264-satellite IRIS2 element and won a €350M French defense satellite contract with sovereign LEO capacity. That combines infrastructure scale with government-backed demand. Why now: The reviewed sources' membership rationale cites current program/contract relevance through support articles 2026-04, and: but were not provided in the payload, limiting precise timing narration. Evidence
Caveats: The reviewed sources does not provide for the membership-support article IDs. Opportunity score is tempered by the absence of kept direct evidence in the ranking payload. |
Risk view
Showing rows 21-40 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 21 | Capella Space highstrong | Opp 8 Risk 4 | Thesis: Risk is present but not thesis-dominant: Capella is undertaking defense-oriented prototype work and broader strategic expansion beyond commercial SAR, which can carry execution complexity, but the reviewed sources contain no direct adverse evidence within the recent evidence window. Why now: The April 8, 2026 SDA award is recent within the recent evidence window and is directly relevant to a 1 year+ horizon because it funds spacecraft design and development for a government demonstration program. Later context articles in April-June 2026 continue to depict Capella as an operating SAR platform with defense exposure. Evidence
Caveats: The positive contract evidence is classified as a neutral supporting fact in the reviewed sources, so direction is inferred from the business substance rather than explicit positive polarity labeling. Several contextual articles mention a planned acquisition or subsidiary status, but time-sensitive ownership/public-status interpretations should be treated cautiously because not all such references are direct, dated transaction-closing evidence. For example, and |
| 22 | Cowboy Space mediummedium | Opp 7 Risk 4 | Thesis: Execution risk is meaningful because the business combines new rocket development with orbital data-center infrastructure, and one cited article says the first launch is expected before the end of 2028, implying a long path from capital raise to operational proof. Why now: Multiple dated articles on May 11, 2026 report Cowboy Space raised $275 million in Series B financing at a $2 billion valuation to build rockets with orbital data-center upper stages, and a TechCrunch article says the company is standing up its own rocket program with a first launch expected before end-2028 Evidence
Caveats: The reviewed sources contain no explicit negative event evidence; risk is inferred from execution complexity and long timeline, not from adverse events. Several supporting rows repeat the same May 11, 2026 financing story and are not independent confirmation. Some supporting article context is undated and should be treated cautiously for recency. |
| 23 | Eutelsat Communications SA mediummedium | Opp 7 Risk 4 | Thesis: Risk remains meaningful because the ranking payload contains no kept direct evidence or representative articles for those claims, so the thesis depends on membership-support statements without available article detail, economics, or recency granularity beyond inclusion in the recent evidence windowed reviewed sources. Why now: The reviewed sources' membership rationale cites current program/contract relevance through support articles 2026-04, and: but were not provided in the payload, limiting precise timing narration. Evidence
Caveats: The reviewed sources does not provide for the membership-support article IDs. Opportunity score is tempered by the absence of kept direct evidence in the ranking payload. |
| 24 | GalaxEye mediummedium | Opp 7 Risk 4 | Thesis: Risk remains meaningful because the reviewed sources does not provide direct evidence of post-launch operational performance, customer revenue conversion, or successful scaling beyond the first satellite. Funding references are inconsistent across articles, and planned next-round financing after commissioning indicates continued capital dependence. Why now: The key timing change is that earlier pre-launch coverage from April 23, 2026 was followed by launch coverage on May 3, 2026/May 4, 2026, and later June 16, 2026 context states the first satellite was launched in May 2026, confirming a business-state transition from concept/pre-launch to deployed asset status. The NSIL resale agreement was reported earlier on February 13, 2026, giving a potential go-to-market bridge once satellite data is available. Evidence
Caveats: Most reviewed sources rows are neutral facts or supporting article context rather than explicit positive evidence. Funding totals vary across articles (~$14.5M, $18.3M, ~$20M), so exact capitalization is uncertain |
| 25 | Globalstar lowweak | Opp 3 Risk 4 | Thesis: Risk is moderate because evidence coverage is absent inside the 90-day recent evidence window, making business-state, ownership, and catalyst timing uncertain for a 1 year+ ranking. Why now: There is effectively no why-now evidence in this row: the recent evidence review shows zero kept rows after the March 29, 2026 cutoff and no representative articles are provided. Caveats: The phase-2 rationale mentions Amazon acquisition-related articles, but those supporting articles are not included in the available evidence for this row. Scores remain low because absence of evidence is not positive evidence. |
| 26 | HyPrSpace lowweak | Opp 3 Risk 4 | Thesis: Risk is somewhat higher than opportunity because launch development is technically demanding and capital intensive, and the reviewed sources provide no available direct event evidence beyond the membership rationale to confirm de-risking milestones within the recent evidence window. Why now: The reviewed sources does not provide recent evidence window-supported article details for the cited raise and development milestones, so the timing case is under-evidenced. Caveats: No representative articles or direct evidence are available after recent evidence filtering. The opportunity view rests only on the membership rationale rather than article-level evidence available for citation. |
| 27 | Impulse Space mediummedium | Opp 8 Risk 4 | Thesis: Main risk is execution risk after a very large private financing round: the reviewed sources confirms capital raised, but does not provide within the recent evidence window direct evidence of completed commercial deployments or revenue realization. The article context says valuation was undisclosed, adding some uncertainty around terms and expectations. Why now: The catalyst is recent and dated: on June 2, 2026/June 3, 2026, Impulse Space disclosed a $500 million Series D and total capital raised above $1 billion, which is highly relevant for a 1 year+ scaling thesis. Evidence
Caveats: Some supportive items are supporting article context and should not be treated as independent confirmation if repeating the same financing announcement. Older commercial contract and government contract references in representative articles are outside the 90-day recent evidence window and therefore not primary recency support here. |
| 28 | Impulse Space lowweak | Opp 4 Risk 4 | Thesis: Risk is not based on direct adverse evidence; instead it reflects defense-program execution uncertainty and lack of currently available corroboration for program status, milestones, or revenue conversion, unavailable in reviewed sources). Why now: Why now is only medium because defense-space prototype work can matter over a 1 year+ horizon, but the reviewed sources' available evidence is empty after recent evidence window, preventing higher-conviction ranking. Caveats: No current evidence is provided for. No direct evidence remained after the recent evidence filter. Potential opportunity rests on membership rationale rather than available corroborated evidence. |
| 29 | Isar Aerospace mediummedium | Opp 5 Risk 4 | Thesis: Risk is also elevated because the same recent context ties the thesis to a near-term launch outcome and milestone execution; the opportunity appears highly contingent on launch success, making binary execution risk material over a 1 year+ horizon. Why now: Recent supporting article context within the recent evidence window supports timing: is dated June 9, 2026 and states Isar raised €270 million and had a June 15-21 Spectrum launch window from Andoya. Date basis is source date. Evidence
Caveats: Evidence is supporting article context only and appears under weak context, not direct dated events. Positive and risk interpretations come from the same article and are not independent confirmation. |
| 30 | ispace lowweak | Opp 3 Risk 4 | Thesis: Reviewed evidence rationale explicitly notes this is ispace's 'second attempt after 2023 failure,' which raises meaningful execution risk for a mission-driven thesis. With no direct positive or negative reviewed evidence, the prior failure context remains the clearest directional risk indicator in the reviewed sources. Why now: The membership support cites: and: The reviewed sources' wording around a second attempt makes mission outcome and execution durability relevant over a 1 year+ horizon, but timing confidence is reduced because no evidence survived into the available set. Caveats: Risk thesis is inferred from reviewed sources rationale mentioning a prior failure, not from available direct negative evidence. No direct evidence confirms current mission status, financing, or customer pipeline. Recency and sequencing of mission milestones cannot be validated from the empty evidence table. |
| 31 | Logos Space Services mediummedium | Opp 6 Risk 4 | Thesis: The same evidence implies substantial execution and engineering risk because the planned network is very large and would use higher-frequency K-, Q- and V-band spectrum that can improve capacity but also pose engineering challenges. Why now: A dated article within the 90-day recent evidence window, with based on April 13, 2026, states that Logos Space Services recently secured FCC approval for a constellation of up to 4,178 broadband satellites and described both target customers and technical architecture, making this a timely strategic-development signal for a 1 year+ horizon. Evidence
Caveats: Evidence is supporting article context, not a richer set of direct dated events/facts. Only one article after recent evidence window; same-article repeated rows are not independent confirmation. |
| 32 | Millennium Space Systems mediummedium | Opp 5 Risk 4 | Thesis: Risk remains moderate because the reviewed sources only provides supporting article context, not direct contract economics, scope allocation to Millennium, or follow-on execution milestones. Why now: The relevant evidence is within the recent evidence window: an April 8, 2026 article said the U.S. Space Force awarded 14 companies more than $1.8 billion in Andromeda contracts and included Boeing's Millennium Space Systems, which is potentially durable over a 1 year+ horizon if tasking converts into meaningful work Evidence
Caveats: Evidence is supporting article context, not a company-specific contract award document or structured positive event row. Reviewed evidence does not show Millennium's individual award size or share of the ceiling value. Same article repeated in weak-context rows is not independent confirmation. |
| 33 | NewOrbit Space mediummedium | Opp 4 Risk 4 | Thesis: Risk is also meaningful because the evidence is undated supporting article context, so recency is uncertain; for a business-state claim like financing and current program maturity, lack of date makes it harder to assess whether the capital raise is still a live catalyst or already absorbed. Why now: Why now is weaker than Aavuus because the article has no publication date. The reviewed sources explicitly says no is available and recency-sensitive claims should be treated cautiously., undated Evidence
Caveats: Evidence is supporting article context only, not direct structured positive event evidence. Publication date is unavailable; recency is uncertain. Single-article support only; no independent confirmation. |
| 34 | NordSpace lowweak | Opp 2 Risk 4 | Thesis: Main risk is evidence insufficiency and likely execution uncertainty around an early-stage space venture rather than confirmed adverse developments; the reviewed sources contain no available direct negative evidence within the recent evidence window and no current dated business-state confirmation, unavailable in reviewed sources). Why now: Why now is weak because coverage data shows zero articles after recent evidence window and zero evidence after the 90-day filter, so there is no current catalyst evidence to support a 1 year+ differentiated view from these reviewed sources. Caveats: No article is provided for the membership-support. No direct positive or negative evidence were available after recent evidence window. Private-company status reduces external validation in these reviewed sources. |
| 35 | NorthStar Earth & Space Inc. lowweak | Opp 2 Risk 4 | Thesis: This row carries elevated information risk because the reviewed sources show no recently retained evidence, no representative articles, and no direct positive or negative evidence, while the ticker/public status implications are time-sensitive and unsupported here. Why now: Why-now is weak because the evidence recent evidence review shows zero kept rows after the 90-day cutoff and the row contains no representative articles or direct evidence, so recency and business state are uncertain in these reviewed sources. Caveats: No evidence were available after the recent evidence window for this row. Any statement about public listing, SPAC timing, or operations would be insufficiently grounded from this row alone. Score is driven by evidence absence, not by documented adverse developments. |
| 36 | Northwood Space mediumweak | Opp 6 Risk 4 | Thesis: Risk is still moderate because the visible reviewed sources does not include the underlying article summary or, so the funding signal lacks fuller context such as use of proceeds, valuation, or milestone cadence. Why now: The rationale references article: and states Northwood Space raised $100 million in a notable spacetech funding deal; that size of financing is plausibly durable over a 1 year+ horizon, though recency cannot be fully validated from the absent article body. Caveats: No representative article or provided in the visible evidence body. No direct evidence after recent evidence window are exposed despite the positive rationale. Funding alone does not prove technical or commercial execution. |
| 37 | Obruta Space Solutions lowweak | Opp 4 Risk 4 | Thesis: Current risk is equal to opportunity because the reviewed sources only shows descriptive company-site context and no direct evidence of contracts, funding, launches, or technical milestones. Without validation, the thesis is still conceptual. Why now: The only dated visible evidence is a company-site page with a May 20, 2026 describing the technology and target markets, which is relevant for strategic positioning but not enough to prove commercial inflection within the next year. Evidence
Caveats: Evidence is company-site descriptive context only. No third-party validation, financing, contract, or deployment evidence is shown. |
| 38 | Observable Space lowweak | Opp 4 Risk 4 | Thesis: The reviewed sources provide no direct operating-niche detail, traction, or milestone evidence beyond the funding mention, so execution risk is relatively elevated despite the financing signal. Why now: Why now is the funding mention tied to article ID: but the reviewed sources provide no, operating specifics, or additional corroborating evidence. Caveats: Funding alone is positive evidence but does not prove business quality. Article ID: is referenced without. |
| 39 | Observable Space mediummedium | Opp 8 Risk 4 | Thesis: Risk remains meaningful because most evidence is supporting source context and neutral facts rather than explicit positive events, and the company still appears to be early-stage, contract-execution dependent, and private. Why now: The timing is favorable because on May 28, 2026 the company was reported to have both closed a $90 million Series A and announced a $94 million U.S. Space Force award, with additional follow-on reporting on June 9, 2026 indicating the contract landed just weeks after the raise, suggesting a recent step-change in funding and government traction for a 1 year+ horizon Evidence
Caveats: Positive direction is inferred from neutral facts plus article summaries; the reviewed sources does not provide explicit positive events. Same-article repeated rows are not independent confirmation. Supporting web-search evidence is context and should be treated below directly cited company evidence. |
| 40 | OMSPACE lowweak | Opp 4 Risk 4 | Thesis: Launch development risk is also high because the evidence only shows an early milestone and a future plan for orbital launch capability by 2027. The reviewed sources contain no retained proof of financing, customer backlog, or follow-on technical milestones, so execution risk is substantial. Why now: The reviewed sources' rationale references article: for a successful sounding-rocket launch and a 2027 orbital-launch target, but the underlying article summary/ is not included here, limiting recency and sequence assessment. Caveats: Evidence is limited to a broad membership rationale without article detail. A sounding-rocket success is meaningfully earlier-stage than an orbital launch business. Risk and opportunity are both elevated relative to peers because the technology path is ambitious but still lightly evidenced. |